Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dronabinol/palmitoylethanolamide - SciSparc

Next Previous
Drug Profile

Dronabinol/palmitoylethanolamide - SciSparc

Alternative Names: SCI-110; THX OSA01; THX RS01; THX-110; THX-TS01

Latest Information Update: 02 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Therapix Biosciences
  • Developer SciSparc; The Israeli Medical Center for Alzheimer's
  • Class Amides; Analgesics; Anti-inflammatories; Antidementias; Antiemetics; Antineoplastics; Antivirals; Appetite stimulants; Behavioural disorder therapies; Cannabinoids; Chromans; Ethanolamines; Muscle relaxants; Neuroprotectants; Non-opioid analgesics; Palmitic acids; Sleep disorder therapies; Small molecules
  • Mechanism of Action Cannabinoid receptor agonists; Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB2 agonists; G-protein-coupled receptor 55 modulators; Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Agitation; Alzheimer's disease; Gilles de la Tourette's syndrome; Sleep apnoea syndrome
  • Discontinued Back pain

Most Recent Events

  • 02 Sep 2025 Discontinued - Phase-II for Back pain in USA (PO) (SciSparc pipeline, September 2025)
  • 16 Dec 2024 SciSparc completes a phase IIa trial in Agitation and Alzheimer's Disease in Israel (PO), prior to December 2024 (NCT05239390)
  • 23 Sep 2024 USFDA approves IND application for Dronabinol/palmitoylethanolamide in Gilles de la Tourette's syndrome

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top